Editta B.
- Country
- Italy
- Department
- 4702: U.O.C. Oncologia Medica
Research Overview
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
- Phase 3 Study of LY4170156 (Sofetabart Mipitecan) ± Bevacizumab versus standard chemotherapy in platinum‑resistant and platinum‑sensitive ovarian cancer
- Open‑Label Rollover Study of Opnurasib (JDQ443) Monotherapy or Combination Therapy in Patients with KRAS G12C‑Mutated Advanced NSCLC or Solid Tumors
Data & Insights
Has run more than one trial at 338 of 641 partner sites.
Specializations
Lung Cancer Research
Specializes in advanced therapeutic approaches for non-small cell lung cancer (NSCLC), with particular focus on targeted therapies and immunotherapy combinations.
- Metastatic NSCLC treatment strategies
- KRAS G12C mutation therapies
- Large-cell neuroendocrine carcinoma
Investigates novel drug combinations including chemoimmunotherapy and targeted molecular approaches.
Breast Cancer Studies
Conducts research in triple-negative breast cancer (TNBC) and hormone receptor-related treatments, focusing on innovative therapeutic combinations.
- Neoadjuvant therapy approaches
- Immunotherapy combinations
- Endocrine-responsive treatments
Explores combination strategies involving chemotherapy and targeted biological agents.
Gastrointestinal Oncology
Leads research in metastatic colorectal cancer treatment, with emphasis on targeted molecular therapies and immunotherapy approaches.
- Sequential therapy strategies
- Circulating tumor DNA applications
- Combination immunotherapy protocols
Develops personalized treatment approaches based on molecular and genetic markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.